近年来,由于头颈部肿瘤患者的平均5年生存率较低,患者的生活品质受到了极大的影响。本文概述了微纤丝相关蛋白2(MFAP2)在头颈部肿瘤中的研究进展。MFAP2作为细胞外基质的重要组成部分,与头颈部肿瘤的发生发展及预后密切相关。近年来的...近年来,由于头颈部肿瘤患者的平均5年生存率较低,患者的生活品质受到了极大的影响。本文概述了微纤丝相关蛋白2(MFAP2)在头颈部肿瘤中的研究进展。MFAP2作为细胞外基质的重要组成部分,与头颈部肿瘤的发生发展及预后密切相关。近年来的研究表明,MFAP2在多种头颈部肿瘤比如鳞状细胞癌和甲状腺癌中明显过表达,并与肿瘤的临床病理特征如TNM分期、肿瘤大小及淋巴结转移相关。MFAP2不仅有望作为早期诊断的生物标志物,还可能成为靶向治疗的新靶点。目前,现有的研究已揭示了MFAP2生物学功能方面的重要性,但其发挥的具体的分子机制还未明确。未来的研究应重点聚焦在MFAP2的作用机制,以及其在临床应用中的潜力,以期为头颈部肿瘤的早期诊断和治疗提供新的思路。In recent years, the average 5-year survival rate of patients with head and neck tumors has remained relatively low, significantly impacting their quality of life. This article summarizes the research progress on microfibril-associated protein 2 (MFAP2) in head and neck tumors. As a crucial component of the extracellular matrix, MFAP2 is closely associated with the development, progression, and prognosis of head and neck tumors. Recent studies have shown that MFAP2 is significantly overexpressed in various head and neck tumors, such as squamous cell carcinoma and thyroid cancer, and is correlated with clinicopathological features such as TNM staging, tumor size, and lymph node metastasis. MFAP2 not only holds potential as a biomarker for early diagnosis but may also serve as a novel target for targeted therapy. While current research has highlighted the importance of MFAP2 in biological functions, its precise molecular mechanisms remain unclear. Future studies should focus on elucidating the mechanisms of MFAP2 and exploring its potential in clinical applications, aiming to provide new insights for the early diagnosis and treatment of head and neck tumors.展开更多
文摘近年来,由于头颈部肿瘤患者的平均5年生存率较低,患者的生活品质受到了极大的影响。本文概述了微纤丝相关蛋白2(MFAP2)在头颈部肿瘤中的研究进展。MFAP2作为细胞外基质的重要组成部分,与头颈部肿瘤的发生发展及预后密切相关。近年来的研究表明,MFAP2在多种头颈部肿瘤比如鳞状细胞癌和甲状腺癌中明显过表达,并与肿瘤的临床病理特征如TNM分期、肿瘤大小及淋巴结转移相关。MFAP2不仅有望作为早期诊断的生物标志物,还可能成为靶向治疗的新靶点。目前,现有的研究已揭示了MFAP2生物学功能方面的重要性,但其发挥的具体的分子机制还未明确。未来的研究应重点聚焦在MFAP2的作用机制,以及其在临床应用中的潜力,以期为头颈部肿瘤的早期诊断和治疗提供新的思路。In recent years, the average 5-year survival rate of patients with head and neck tumors has remained relatively low, significantly impacting their quality of life. This article summarizes the research progress on microfibril-associated protein 2 (MFAP2) in head and neck tumors. As a crucial component of the extracellular matrix, MFAP2 is closely associated with the development, progression, and prognosis of head and neck tumors. Recent studies have shown that MFAP2 is significantly overexpressed in various head and neck tumors, such as squamous cell carcinoma and thyroid cancer, and is correlated with clinicopathological features such as TNM staging, tumor size, and lymph node metastasis. MFAP2 not only holds potential as a biomarker for early diagnosis but may also serve as a novel target for targeted therapy. While current research has highlighted the importance of MFAP2 in biological functions, its precise molecular mechanisms remain unclear. Future studies should focus on elucidating the mechanisms of MFAP2 and exploring its potential in clinical applications, aiming to provide new insights for the early diagnosis and treatment of head and neck tumors.
